Ketol-acid reductoisomerase: An important antituberculosis drug target

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1147297

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Due to the increasing prevalence of drug resistance, new antituberculosis medications are urgently needed. Here, we will use rational structure-based approaches to design new inhibitors of ketolacid reductoisomerase (KARI), an enzyme whose activity is essential to the survival of this pathogen that resides in the lungs of humans. These inhibitors will be converted into prodrug formulations for optimal activity in cell-based assays and in mice infected with this pathogen.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $690,113.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Structural Biology (incl. Macromolecular Modelling)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Mycobacterium tuberculosis | drug discovery | medicinal chemistry | rational drug design | structural biology

Related Links